You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 11,771,701


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,771,701 protect, and when does it expire?

Patent 11,771,701 protects JYLAMVO and is included in one NDA.

This patent has twenty-three patent family members in eighteen countries.


Drugs Protected by US Patent 11,771,701

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Shorla JYLAMVO methotrexate SOLUTION;ORAL 212479-001 Nov 29, 2022 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y TREATMENT OF ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH AN ORAL SOLUTION OF METHOTREXATE ⤷  Subscribe
Shorla JYLAMVO methotrexate SOLUTION;ORAL 212479-001 Nov 29, 2022 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y TREATMENT OF ADULTS WITH MYCOSIS FUNGOIDES WITH AN ORAL SOLUTION OF METHOTREXATE ⤷  Subscribe
Shorla JYLAMVO methotrexate SOLUTION;ORAL 212479-001 Nov 29, 2022 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS WITH AN ORAL SOLUTION OF METHOTREXATE ⤷  Subscribe
Shorla JYLAMVO methotrexate SOLUTION;ORAL 212479-001 Nov 29, 2022 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y TREATMENT OF ADULTS WITH RHEUMATOID ARTHRITIS WITH AN ORAL SOLUTION OF METHOTREXATE ⤷  Subscribe
Shorla JYLAMVO methotrexate SOLUTION;ORAL 212479-001 Nov 29, 2022 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y TREATMENT OF ADULTS WITH SEVERE PSORIASIS WITH AN ORAL SOLUTION OF METHOTREXATE ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,771,701

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2015340373 ⤷  Subscribe
Canada 3002493 ⤷  Subscribe
China 107106485 ⤷  Subscribe
China 116747190 ⤷  Subscribe
Cyprus 1125033 ⤷  Subscribe
Denmark 3212237 ⤷  Subscribe
European Patent Office 3212237 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.